Xenon Corp (XENE) Market Value to Book Value Ratio
The Xenon Pharmaceuticals (XENE) price chart reflects the dynamics of a company developing cutting-edge treatments for neurological pathologies, where demand for new therapies remains extremely high. Operations are funded through investments and partnerships, with the current figure standing at 2.81. Growth prospects depend on the results of XEN1101 Phase 3 trials, regulatory approval, and the volume of development funding.
Xenon Pharmaceuticals Inc. (XENE) - metric breakdowns and financial figures
- share price and expert price forecast:
- market capitalization details:
- book capitalization data:
- debt and solvency information:
Debt to Equity Xenon Pharmaceuticals|XENE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Xenon Pharmaceuticals Inc|XENE - Company Cumulative Debt|Debt to Book Value Xenon Pharmaceuticals Inc|XENE - Company Long-Term Indebtedness|Company Short-Term Debts Xenon Pharmaceuticals|Quick Liquidity xenon-pharma.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:Xenon Pharmaceuticals, XENE
For Xenon Pharmaceuticals (XENE), the relative capitalization metric reflects market confidence in the success of non-cyclical epilepsy developments, which depend primarily on regulatory decisions. This metric is calculated as the ratio of the issuer's market value to its net assets, allowing investors to quickly assess the business's actual solvency and the risk of capital impairment during periods of market volatility.
Key competitors
BIIB: Market Capitalization to Book Value Ratio|Market-to-Book Ratio neurocrine.com (NBIX)|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|VKTX - Market-to-Book Ratio|Supernus Pharmaceuticals - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio catalystpharma.com CPRX|DNLI - Market Value to Book Value Ratio|Market Value to Book Value HRMY (Harmony Biosciences Inc)|Biohaven Pharmaceutical (BHVN) - Market Value to Book Value Ratio|Market-to-Book Ratio Amylyx Corp (AMLX)|Market Cap to Net Assets Ratio TRVI|Capitalization to Book Value Ratio PRAX (praxismedicines.com)|Market Capitalization to Book Value Ratio AVXL|CBLL - Market-to-Book Ratio|Market Value to Book Value Ratio prothena.com PRTA|ALEC: Capitalization to Book Value Ratio|ANNX - Market Value to Book Value Ratio|Market-to-Book Ratio Omeros Corporation|Neurogene (NGNE) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio ACIU|Market Cap to Net Assets Ratio VYGR|NMRA: Market Value to Book Value|Market Value to Book Value Ratio Scilex Holding Company (SCLX)|TVGN: Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio ACOG (Alpha Cognition Inc.)|Market Value to Book Value CGTX|Inhibikase - Market Capitalization to Book Value Ratio|SAVA - Market Capitalization to Book Value Ratio|assertiotx.com (ASRT) - Market Value to Book Value Ratio|Coya Therapeutics - Market Value to Book Value|Market Value to Book Value Ratio VistaGen Therapeutics, Inc.|Market Cap to Net Assets Ratio Ovid Rx (OVID)|Market Capitalization to Book Value Ratio ABOS|Market Capitalization to Book Value Ratio CervoMed Corporation (CRVO)|Market Capitalization to Book Value Ratio ATHE (Alterity Therapeutics Limited)|CLNN - Market Cap to Net Assets Ratio|PepGen Corp - Market Capitalization to Book Value Ratio|Market-to-Book Ratio jupiterneurosciences.com|RLMD (Relmada) - Market Cap to Net Assets Ratio|Annovis Bio Corporation (ANVS) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio GRCE|AIFF (fireflyneuro.com) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio KLTO|Market Capitalization to Book Value neurosense-tx.com|Market Capitalization to Book Value Ratio RVPH (Reviva Pharmaceuticals Holdings)|MTVA - Market Cap to Net Assets Ratio|NeurAxis, Inc. - Market Capitalization to Book Value Ratio|HSDT - Market Capitalization to Book Value Ratio|passagebio.com (PASG) - Market Value to Book Value Ratio|NEUP (Neuphoria Therapeutics) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Minerva Neurosciences Corp|Athira Pharma Corp (ATHA) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio ADXN (Addex Therapeutics)|alzamend.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio CYCN (Cyclerion Therapeutics, Inc.)|Protagenic Therapeutics Inc. (PTIX) - Market-to-Book Ratio|KTTA - Market Value to Book Value Ratio|CRGT (Cortigent, Inc.) - Capitalization to Book Value Ratio|ATXI: Market Capitalization to Book Value Ratio|Market-to-Book Ratio brainstorm-cell.com (BCLI)|Market Value to Book Value Ratio Cara Therapeutics|Capitalization to Book Value Ratio CHRO (Chromocell Therapeutics Corp)|Market Capitalization to Book Value Ratio ELYM|ITCI - Market-to-Book Ratio|Longboard Pharmaceuticals - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio marinuspharma.com MRNS|NKGN - Market Value to Book Value Ratio|Market Value to Book Value NRBO (NeuroBo Pharmaceuticals Inc)|Sage Therapeutics, Inc (SAGE) - Market Value to Book Value Ratio|Market-to-Book Ratio Synaptogenix, Inc (SNPX)|Market Cap to Net Assets Ratio TRVN|Capitalization to Book Value Ratio VIGL (Vigil Neuro)|Market Capitalization to Book Value Ratio WENA|CERE - Market-to-Book Ratio